
Parallel Bio is a biotechnology company that has developed the first platform replicating the human immune system in a dish for drug discovery and development. Their platform uses immune organoids—functioning in-vitro replicas of human lymph nodes—combined with AI and high-throughput automation to design and test immunotherapies that work in humans from the start. This approach transcends traditional animal models, which are poor predictors of human outcomes, enabling faster, cheaper, and more effective drug development with reduced risk and cost. Parallel Bio's technology allows for population-scale testing, modeling diverse human immune responses to create safer and more effective therapies. The company actively collaborates with major pharmaceutical and biotech companies, aiming to transform immunotherapy discovery and accelerate the delivery of treatments for previously untreatable diseases. Founded in 2021 and based in Cambridge, Massachusetts, Parallel Bio leverages cutting-edge bioengineering, machine learning, and robotics to revolutionize drug discovery by providing a clinical trial in a dish.

Parallel Bio is a biotechnology company that has developed the first platform replicating the human immune system in a dish for drug discovery and development. Their platform uses immune organoids—functioning in-vitro replicas of human lymph nodes—combined with AI and high-throughput automation to design and test immunotherapies that work in humans from the start. This approach transcends traditional animal models, which are poor predictors of human outcomes, enabling faster, cheaper, and more effective drug development with reduced risk and cost. Parallel Bio's technology allows for population-scale testing, modeling diverse human immune responses to create safer and more effective therapies. The company actively collaborates with major pharmaceutical and biotech companies, aiming to transform immunotherapy discovery and accelerate the delivery of treatments for previously untreatable diseases. Founded in 2021 and based in Cambridge, Massachusetts, Parallel Bio leverages cutting-edge bioengineering, machine learning, and robotics to revolutionize drug discovery by providing a clinical trial in a dish.
Founded: 2021
Headquarters: Cambridge / Watertown, Massachusetts
Product: Human immune organoids + AI + automation for 'trial-in-a-dish' drug discovery
Recent financing: Series A announced Jun 11, 2025 (lead: AIX Ventures)
| Company |
|---|
Preclinical immunotherapy discovery and safety prediction where animal models are poor predictors of human immune responses.
2021
Biotechnology
21000000
Series A announced Jun 11, 2025
“Includes venture firms and notable angel/backers such as AIX Ventures, Refactor Capital, Breakout Ventures, Y Combinator, Jeff Dean, and Marc Benioff”
At Parallel Bio, we are leveraging the human immune system to unlock safer, more effective drugs. We believe immunotherapies are the future of medicine, but their discovery is hindered by outdated models that fail to capture the complexity of the human immune system.
Our platform overcomes these challenges by combining best-in-class human immune organoids with massive scale and advanced computational methods, including AI and machine learning. This allows us to generate unprecedented, population-scale insights into human health and disease.
We can rapidly discover new drugs that we know will work in patients from the start and understand how they will perform across an entire population—something not possible with today's technology. This knowledge will allow us to engineer therapies that will work for as many people as possible, ensuring a safe and effective cure for everyone.
We are a fast-paced, venture-backed company at a pivotal moment of growth. Join us on our journey as we create new tools to push the boundaries of what is possible.
The Role Parallel Bio is hiring a Business Development Lead, European Public Sector to support and contribute to our EU/EEA growth function, reporting to the Head of Business Development, Government (US focus). This senior individual contributor role supports end-to-end capture for non-dilutive funding and partnerships across key European agencies and programs such as Horizon Europe, EIC Pathfinder/Challenges, IMI/IMI2-Accelerate, EMA qualification pathways, and Austrian funders (e.g., FFG Austria, FWF, AWS, VBA, etc).
The role emphasizes execution support with growing regulatory-science literacy to identify opportunities where EMA/regulatory adoption/validation matters, and to help craft proposals with credible regulatory elements (e.g., context of use, validation approach) alongside internal scientific leadership, the US BD Director, and external advisors.
Responsibilities European Pipeline & Capture Support
Stakeholder Relationship Support
Regulatory Support
Proposal Support
Teaming & Partnerships
Award Transition Support
Qualifications Required
Preferred
Parallel Bio is an equal opportunity employer committed to fostering an inclusive and respectful workplace. We encourage applications from individuals of all backgrounds, regardless of age, gender, ethnicity, religion, disability, or sexual orientation. Compensation Range: €85K